文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

NRG Oncology/RTOG 0622首次报告:钐-153后挽救性前列腺床放疗的2期试验

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-21

NRG Oncology/RTOG 0622是一项单臂2期试验,纳入60例根治性前列腺切除术后生化失败且无骨转移证据的高危前列腺癌患者,先接受153Sm lexidronam 2.0 mCi/kg单次静脉注射,随后行前列腺床挽救性EBRT 64.8-70.2 Gy,不允许ADT。主要终点12周内PSA反应率仅13.5%(7/52),未达25%的假设值;2年无进展率25.5%,生化失败率64.4%,方案耐受性良好。

要点

  • 153Sm后挽救性EBRT的PSA反应率13.5%,未达预设25%主要终点。
  • 2年无进展率25.5%,生化失败率64.4%。
  • 3-4级血液学不良事件16/60例,无5级;放疗耐受良好。

核心结论

  • NRG Oncology RTOG 0622未达到PSA反应主要终点,但153Sm联合挽救性EBRT方案耐受性良好。
  • 尽管毒性特征支持在高危疾病中研究153Sm,但在接受EBRT的男性中可能无获益。

研究设计与样本

  • 单臂2期试验,纳入60例pT2-T4、N0-1、M0根治性前列腺切除术后生化失败且无临床骨转移证据的患者。
  • 生化失败标准为PSA>1.0 ng/mL,或Gleason评分9-10且PSA>0.2 ng/mL,或N1且PSA>0.2 ng/mL。
  • 患者接受153Sm 2.0 mCi/kg单次静脉注射,随后前列腺床挽救性EBRT 64.8-70.2 Gy,每次1.8 Gy,不允许ADT。
  • 主要终点为接受153Sm后12周内PSA反应,次要终点包括方案完成率、12和24周血液学毒性及其他AE、2年无进展率。
  • 中位随访3.97年。

主要发现

  • 52例可评估患者中7例(13.5%)达到PSA反应,低于25%的假设值。
  • 2年无进展率为25.5%(95%CI 14.4%-36.7%),生化失败率为64.4%(95%CI 50.5%-75.2%)。
  • 153Sm耐受良好,60例中16例发生3-4级血液学AE,无5级血液学AE。
  • 放疗耐受良好,无3-5级急性放疗相关AE,1例3-4级晚期放疗相关AE,无5级晚期放疗相关AE。

关键数值与推荐

  • PSA反应定义为接受153Sm后12周内PSA下降,具体定义未在摘要中详述。
  • 生化失败标准:PSA>1.0 ng/mL;或Gleason评分9-10且PSA>0.2 ng/mL;或N1且PSA>0.2 ng/mL。
  • 153Sm剂量2.0 mCi/kg静脉单次给药;EBRT剂量64.8-70.2 Gy,1.8 Gy/次。

临床怎么用

  • 对于根治性前列腺切除术后生化失败且无骨转移证据的高危患者,153Sm联合挽救性EBRT未显示优于预设目标的PSA反应。
  • 该方案血液学毒性以3-4级为主且可接受,但鉴于主要终点未达到,不支持在EBRT基础上常规加用153Sm。

局限性

  • 单臂2期设计,无对照组,样本量60例,可评估PSA反应者52例。
  • 主要终点未达到,结果不支持进一步在EBRT基础上常规联合153Sm。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the utility of 153Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases. PATIENTS AND METHODS: Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these biochemical failure criteria: (1) prostate-specific antigen (PSA) > 1.0 ng/mL; (2) PSA > 0.2 ng/mL if Gleason score 9 to 10; or (3) PSA > 0.2 ng/mL if N1. Patients received 153Sm (2.0 mCi/kg intravenously × 1) followed by salvage external beam radiation therapy (EBRT) to the prostatic fossa (64.8-70.2 Gy in 1.8-Gy daily fractions). No androgen deprivation therapy was allowed. The primary objective was PSA response within 12 weeks of receiving 153Sm. The secondary objectives were to: (1) assess the completion rate for the regimen of 153Sm and EBRT; (2) evaluate the hematologic toxicity and other adverse events (AEs) at 12 and 24 weeks; and (3) determine the freedom from progression rate at 2 years. RESULTS: A total of 60 enrolled eligible patients were included in this analysis. Median follow-up was 3.97 years. A PSA response was achieved in 7 of 52 evaluable patients (13.5%), compared with the 25% hypothesized. The 2-year freedom from progression rate was 25.5% (95% confidence interval 14.4%-36.7%), and the biochemical failure rate was 64.4% (95% CI 50.5%-75.2%). Samarium-153 was well tolerated, with 16 (of 60) grade 3 to 4 hematologic AEs and no grade 5 hematologic AEs. Radiation therapy was also well tolerated, with no grade 3 to 5 acute radiation therapy-related AEs and 1 grade 3 to 4 and no grade 5 late radiation therapy-related AEs. CONCLUSIONS: Trial NRG Oncology RTOG 0622 did not meet its primary endpoint of PSA response, although the regimen of 153Sm and salvage EBRT was well tolerated. Although the toxicity profile supports study of 153Sm in high-risk disease, it may not be beneficial in men receiving EBRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Valicenti RK, Pugh SL, Trabulsi EJ, et al. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413282. doi:10.1016/j.ijrobp.2017.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。